You are here

Bristol-Myers Squibb Drug Fails Liver Cancer Trial

The company reported that the study did not meet its primary objective of overall survival, based on a non-inferiority statistical design.

BRISK-FL is a randomized, double-blind, multicenter, phase III study of the investigational agent brivanib versus sorafenib in patients with advanced HCC who have not received prior systemic treatment.

Bristol-Myers Squibb and the lead investigators plan to present the findings of the study at an upcoming scientific meeting.

Brivanib alaninate is the alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity.

Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.

For more information, visit the BMS Web site.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year